JP2014522868A5 - - Google Patents

Download PDF

Info

Publication number
JP2014522868A5
JP2014522868A5 JP2014523080A JP2014523080A JP2014522868A5 JP 2014522868 A5 JP2014522868 A5 JP 2014522868A5 JP 2014523080 A JP2014523080 A JP 2014523080A JP 2014523080 A JP2014523080 A JP 2014523080A JP 2014522868 A5 JP2014522868 A5 JP 2014522868A5
Authority
JP
Japan
Prior art keywords
preparation
protein
acid sequence
amino acid
chimeric cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014523080A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014522868A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/048631 external-priority patent/WO2013019652A1/en
Publication of JP2014522868A publication Critical patent/JP2014522868A/ja
Publication of JP2014522868A5 publication Critical patent/JP2014522868A5/ja
Pending legal-status Critical Current

Links

JP2014523080A 2011-07-29 2012-07-27 精製タンパク質 Pending JP2014522868A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161513453P 2011-07-29 2011-07-29
US61/513,453 2011-07-29
US201261591727P 2012-01-27 2012-01-27
US61/591,727 2012-01-27
PCT/US2012/048631 WO2013019652A1 (en) 2011-07-29 2012-07-27 Purified proteins

Publications (2)

Publication Number Publication Date
JP2014522868A JP2014522868A (ja) 2014-09-08
JP2014522868A5 true JP2014522868A5 (cg-RX-API-DMAC7.html) 2015-09-17

Family

ID=46682907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014523080A Pending JP2014522868A (ja) 2011-07-29 2012-07-27 精製タンパク質

Country Status (10)

Country Link
US (1) US20140341843A1 (cg-RX-API-DMAC7.html)
EP (1) EP2736524A1 (cg-RX-API-DMAC7.html)
JP (1) JP2014522868A (cg-RX-API-DMAC7.html)
CN (1) CN104066439A (cg-RX-API-DMAC7.html)
AU (1) AU2012290379A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014002173A2 (cg-RX-API-DMAC7.html)
CA (1) CA2843197A1 (cg-RX-API-DMAC7.html)
RU (1) RU2014107743A (cg-RX-API-DMAC7.html)
SG (1) SG10201606218WA (cg-RX-API-DMAC7.html)
WO (1) WO2013019652A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20230776T1 (hr) 2010-07-29 2023-10-27 Buzzard Pharmaceuticals AB Himerni antagonisti receptora il-1 tipa i
JP6450364B2 (ja) * 2013-03-13 2019-01-09 セセン バイオ, インコーポレイテッド 眼送達のためのキメラサイトカイン製剤
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
DK3461891T3 (da) * 2014-01-24 2020-08-10 Am-Pharma Bv Nedstrømsbehandling af en alkalisk phosphatase
WO2015138844A1 (en) * 2014-03-13 2015-09-17 Eleven Biotherapeutics, Inc. Methods for production of stable chimeric cytokine protein formulations in blow fill seal containers
SG11201702757YA (en) * 2014-10-23 2017-05-30 Ngm Biopharmaceuticals Inc Pharmaceutical compositions comprising peptide variants and methods of use thereof
TW201702380A (zh) * 2015-02-27 2017-01-16 再生元醫藥公司 宿主細胞蛋白質修飾
CN104710527B (zh) * 2015-02-28 2018-08-24 苏州金盟生物技术有限公司 一种生物制品的内毒素去除方法
CN115598231B (zh) * 2016-08-15 2025-11-18 豪夫迈·罗氏有限公司 定量包含非离子表面活性剂和多肽的组合物中非离子表面活性剂的层析方法
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4770781A (en) * 1986-03-03 1988-09-13 Merck & Co., Inc. Purification of human interleukin-1 species
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4801686A (en) * 1986-09-04 1989-01-31 Immunex Corporation Purification of recombinant interleukin-1
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
JP2799483B2 (ja) * 1988-03-09 1998-09-17 大塚製薬株式会社 インターロイキン−1β組成物の安定化方法
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
HK1006856A1 (en) * 1989-11-29 1999-03-19 Amgen Inc. Production of recombinant human interleukin-1 inhibitor
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
ATE257389T1 (de) * 1992-09-17 2004-01-15 Amgen Inc Pharmazeutische zusammensetzungen mit interleukin-1 inhibitoren
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
EP0938501B1 (en) * 1996-06-07 2004-07-28 AVENTIS BULK S.p.A. Process for the purification of human interleukin-1 receptor antagonist from recombinant e. coli
CA2273852C (en) * 1996-12-06 2009-09-29 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
PL1729810T3 (pl) * 2004-04-02 2019-02-28 Swedish Orphan Biovitrum Ab (Publ) Sposoby agregacji IL-1ra
US7700318B2 (en) * 2004-08-25 2010-04-20 Amprotein Corporation Chimeric polypeptide and use thereof
CA2589802A1 (en) * 2004-12-02 2006-06-08 Domantis Limited Plad domain peptides with increased serum half life due to conjugation to domain antibodies
US8563521B2 (en) 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
WO2011063195A2 (en) * 2009-11-20 2011-05-26 Dr. Reddy's Laboratories Ltd. Purification of modified cytokines
HRP20230776T1 (hr) * 2010-07-29 2023-10-27 Buzzard Pharmaceuticals AB Himerni antagonisti receptora il-1 tipa i
WO2012103240A2 (en) * 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Receptor binding agents

Similar Documents

Publication Publication Date Title
US8329871B2 (en) Process of purifying coagulation factor VIII
Lampi et al. Lens proteomics: analysis of rat crystallin sequences and two-dimensional electrophoresis map
US7999085B2 (en) Enhanced capacity and purification of protein by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
JP7270085B2 (ja) ナノ粒子製剤
EP3325614B1 (en) Methods for purifying adenovirus vectors
JP2010529958A5 (cg-RX-API-DMAC7.html)
WO2015067781A1 (en) New methods to produce active tert
RU2014107743A (ru) Очищенные белки
RU2019109975A (ru) Способы очистки антител
JP2008054693A (ja) 酵母宿主から真性のigfを精製するための方法
JP6232130B2 (ja) ダルベポエチンアルファの精製方法
CA2956316C (en) Method for purifying antibodies
CA3014567C (en) Method for producing activated hepatocyte growth factor (hgf)
Liu et al. TbPIF1, a Trypanosoma brucei mitochondrial DNA helicase, is essential for kinetoplast minicircle replication
US20250215050A1 (en) Compositions and methods for purifying biological fluids
US11584777B2 (en) Method for purifying a sulfatase protein
Balagurunathan et al. Enhancement of stability of recombinant streptokinase by intracellular expression and single step purification by hydrophobic interaction chromatography
US20200131225A1 (en) Methods of purification of albumin fusion proteins
CA2847818A1 (en) Methods for processing coagulation factors
US11919924B1 (en) Methods of purifying and producing an adalimumab antibody
Rajamanickam et al. Comparison of Purification Strategies of Three Horseradish PeroxidaseIsoenzymes Recombinantly Produced in Pichia pastoris
JP5750471B2 (ja) 組換え体ヒトfshの製造方法
RU2683950C1 (ru) Способ очистки рекомбинантного тканевого активатора плазминогена для медицинского применения
JP2017186278A (ja) 標的タンパク質の精製方法
JP2001139600A (ja) Il−6r・il−6融合蛋白質の精製方法